secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2022-04-20T23:59:59+00:00
Accession:  0000950170-22-005825
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma amends Tasly license for STRO-002; gets $25M initial, up to $350M in milestones
--------------------------------------------------------------------------------

- Amendment to Tasly license for STRO-002 in Greater China (China, HK, Macau, Taiwan).
- Initial payment revised to $25M; $15M escrow in Q2 2022 payable on regulatory milestones.
- Additional potential milestone payments up to $350M for development, regulatory, commercialization.
- Tasly retains exclusive rights to develop and commercialize STRO-002 in the region.
- Amendment effective April 18, 2022; full terms to be filed in Q2 2022 10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017022005825/0000950170-22-005825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017022005825/stro-20220418.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-005825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer